These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291 [TBL] [Abstract][Full Text] [Related]
12. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681 [TBL] [Abstract][Full Text] [Related]
13. Nuclear imaging of neuroendocrine tumours. Sundin A; Garske U; Orlefors H Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266 [TBL] [Abstract][Full Text] [Related]
14. Nuclear medicine procedures in the diagnosis of NET: a historical perspective. Maffione AM; Karunanithi S; Kumar R; Rubello D; Alavi A PET Clin; 2014 Jan; 9(1):1-9. PubMed ID: 25029929 [TBL] [Abstract][Full Text] [Related]
15. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Chua S; Gnanasegaran G; Cook GJ Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221 [TBL] [Abstract][Full Text] [Related]
16. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906 [TBL] [Abstract][Full Text] [Related]
17. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers. Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450 [TBL] [Abstract][Full Text] [Related]
18. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes. Shamim SA; Kumar A; Kumar R PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675 [TBL] [Abstract][Full Text] [Related]
19. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518 [TBL] [Abstract][Full Text] [Related]
20. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Papadakis GZ; Karantanas AH; Marias K; Millo C Eur J Radiol; 2021 Oct; 143():109932. PubMed ID: 34482177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]